Electroacupuncture for Cancer-Related Cognitive Impairment: A Clinical Feasibility Study. (May 2022)

• Record Type: Journal Article
• Authors: Lyu, Yee Ran; Lee, Hye-Yoon; Park, Hyo-Ju; Kwon, O-jin; Kim, Ae-Ran; Jung, In Chul; Park, Yang-Chun; Cho, Jung-Hyo; Kim, Jung-Eun; Kim, Mikyung; Lee, Jun-Hwan; Kim, Joo-Hee
• Is Part Of: Integrative cancer therapies. Volume 21(2022)
• Publication Date: 2022-05
• Subjects: electroacupuncture -- cancer-related cognitive impairment -- cancer -- integrative medicine -- feasibility clinical trial; Cancer -- Alternative treatment -- Periodicals; 616.99406
• DOI: 10.1177/15347354221098983
• Languages: English
• ISSNs: 1534-7354

Abstract

Background: Cancer-related cognitive impairment (CRCI) is a significant problem for cancer patients, as the number of cancer survivors experiencing cognitive impairments is increasing in the absence of standard treatment. There have been attempts to improve the cognitive function of patients with cancer using acupuncture; however, no studies have been conducted using electroacupuncture. Thus, we designed a preliminary study to investigate the feasibility of a clinical trial using electroacupuncture in CRCI patients. Methods: We conducted a single-arm, pilot, clinical trial to investigate the feasibility of a study protocol for further large-scale clinical trials of electroacupuncture in CRCI patients. All participants were treated with electroacupuncture twice a week for 30 minutes at a time, for 8 weeks on acupoints GV20, GV24, EX-HN1, and GB20, HT7, PC6, and KI3. Both subjective and objective outcomes of cognitive function, quality of life (QoL), and psychological factors were measured in all participants at baseline, week 4, 8, and 12. For safety assessment, vital signs, laboratory examinations, and adverse events (AEs) were observed throughout the trial. Results: A total of 12 participants were enrolled at Daejeon and Dunsan Korean Medicine Hospital of Daejeon University from 21 April 2017 to 31 January 2018. After 8 weeks of treatment, electroacupuncture significantly improved both subjective and objective cognitive outcomes, including the perceived cognitive impairments scale of the Functional Assessment of Cancer Therapy-Cognitive Function, QoL scale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire-C30, Korean version of Montreal Cognitive Assessment, Boston Naming Test, Seoul Verbal Learning Test, and Rey Complex Figure Test. During the entire trial period, 19 AEs were observed, with no serious AEs. Additionally, it was found that all feasibility outcomes, including recruitment, completion, and adherence rates, achieved successful results as the ratio exceeded 0.8. Conclusion: Our study results revealed that electroacupuncture improved cognitive complaints in cancer patients, and we expect electroacupuncture to be a safe and effective management therapy for CRCI patients. These feasibility trial results will be used as preliminary data for future randomized controlled clinical trials. Trial registration number: Korean Clinical Trial Registry (KCT0002168).